Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
243 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02091141 | My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors | completed | Phase 2 | 673 | Genentech, Inc.INDUSTRY | 1 | Jul 23, 2024 | clinicaltrials |
| NCT04434469 | A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma | completed | Phase 1 | 27 | Genentech, Inc.INDUSTRY | 4 | Jul 3, 2024 |
| clinicaltrials |
| NCT04180176 | Prospective Clinicogenomic Program(PCG) | completed | Phase 4 | 945 | Genentech, Inc.INDUSTRY | 1 | Jan 17, 2024 | clinicaltrials |
| NCT01485861 | Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy | completed | Phase 1 / Phase 2 | 298 | Genentech, Inc.INDUSTRY | 9 | Sep 14, 2023 | clinicaltrials |
| NCT01992653 | A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 85 | Genentech, Inc.INDUSTRY | 2 | Mar 14, 2023 | clinicaltrials |
| NCT03916744 | A Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer | completed | Phase 1 | 75 | Genentech, Inc.INDUSTRY | 5 | Mar 10, 2023 | clinicaltrials |
| NCT00312728 | A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT) | completed | Phase 2 | 115 | Genentech, Inc.INDUSTRY | 0 | Jan 6, 2023 | clinicaltrials |
| NCT00543712 | A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g) | terminated | Phase 2 | 15 | Genentech, Inc.INDUSTRY | 2 | Dec 13, 2022 | clinicaltrials |
| NCT00388206 | A Study of Avastin in Combination With Chemotherapy for Treatment of Colorectal Cancer and Non-Small Cell Lung Cancer (ARIES)(ARIES) | completed | — | 3,998 | Genentech, Inc.INDUSTRY | 0 | Dec 12, 2022 | clinicaltrials |
| NCT00664898 | A Study of the Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 18 | Genentech, Inc.INDUSTRY | 0 | Dec 12, 2022 | clinicaltrials |
| NCT00909740 | A Study of the Safety and Pharmacokinetics of MEGF0444A Administered to Patients With Advanced Solid Tumors | completed | Phase 1 | 30 | Genentech, Inc.INDUSTRY | 0 | Dec 12, 2022 | clinicaltrials |
| NCT04395508 | An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic | approved for marketing | — | — | Genentech, Inc.INDUSTRY | 1 | Jul 5, 2022 | clinicaltrials |
| NCT01991184 | A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia. | completed | Phase 1 | 24 | Genentech, Inc.INDUSTRY | 2 | Jun 21, 2022 | clinicaltrials |
| NCT02410512 | A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 610 | Genentech, Inc.INDUSTRY | 7 | Apr 1, 2022 | clinicaltrials |
| NCT01896531 | A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer | completed | Phase 2 | 153 | Genentech, Inc.INDUSTRY | 11 | Mar 2, 2022 | clinicaltrials |
| NCT01362374 | Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors | completed | Phase 1 | 122 | Genentech, Inc.INDUSTRY | 4 | Jan 12, 2022 | clinicaltrials |
| NCT01823835 | A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer | terminated | Phase 1 / Phase 2 | 152 | Genentech, Inc.INDUSTRY | 4 | Jun 18, 2021 | clinicaltrials |
| NCT02569801 | A Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor (AI) Therapy(HydranGea) | terminated | Phase 2 | 71 | Genentech, Inc.INDUSTRY | 6 | Apr 23, 2021 | clinicaltrials |
| NCT02162719 | A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors(LOTUS) | completed | Phase 2 | 124 | Genentech, Inc.INDUSTRY | 8 | Mar 10, 2021 | clinicaltrials |
| NCT00130728 | A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer | completed | Phase 3 | 636 | Genentech, Inc.INDUSTRY | 1 | Jan 14, 2021 | clinicaltrials |
| NCT01633970 | A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 240 | Genentech, Inc.INDUSTRY | 1 | Oct 8, 2020 | clinicaltrials |
| NCT02316509 | A Study of GDC-0927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer | completed | Phase 1 | 43 | Genentech, Inc.INDUSTRY | 2 | Oct 5, 2020 | clinicaltrials |
| NCT03961100 | A Performance and Bioavailability Study of Entrectinib in Healthy Volunteers. | completed | Phase 1 | 31 | Genentech, Inc.INDUSTRY | 1 | Sep 7, 2020 | clinicaltrials |
| NCT01656642 | A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma | completed | Phase 1 | 67 | Genentech, Inc.INDUSTRY | 1 | Jul 21, 2020 | clinicaltrials |
| NCT02848651 | A Study of Atezolizumab as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer(B-F1RST) | completed | Phase 2 | 153 | Genentech, Inc.INDUSTRY | 1 | Apr 28, 2020 | clinicaltrials |
| NCT01564251 | A Study of GDC-0575 Alone and in Combination With Gemcitabine in Participants With Refractory Solid Tumors or Lymphoma | completed | Phase 1 | 104 | Genentech, Inc.INDUSTRY | 2 | Feb 25, 2020 | clinicaltrials |
| NCT01691898 | A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)(ROMULUS) | completed | Phase 1 / Phase 2 | 231 | Genentech, Inc.INDUSTRY | 6 | Feb 21, 2020 | clinicaltrials |
| NCT02092792 | A Study Evaluating the Safety of Escalating Doses of DLYE5953A in Patients With Refractory Solid Tumors | completed | Phase 1 | 42 | Genentech, Inc.INDUSTRY | 1 | Feb 12, 2020 | clinicaltrials |
| NCT02608034 | A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State | completed | Phase 1 | 32 | Genentech, Inc.INDUSTRY | 4 | Feb 12, 2020 | clinicaltrials |
| NCT02320487 | A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 102 | Genentech, Inc.INDUSTRY | 1 | Feb 11, 2020 | clinicaltrials |
| NCT02219724 | A Study to Assess Safety and Pharmacokinetics of MOXR0916 in Participants With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 174 | Genentech, Inc.INDUSTRY | 6 | Feb 5, 2020 | clinicaltrials |
| NCT01059630 | A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN) | completed | Phase 3 | 413 | Genentech, Inc.INDUSTRY | 14 | Jan 13, 2020 | clinicaltrials |
| NCT01685892 | A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia | completed | Phase 1 | 82 | Genentech, Inc.INDUSTRY | 2 | Jan 10, 2020 | clinicaltrials |
| NCT00567190 | A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer(CLEOPATRA) | completed | Phase 3 | 808 | Genentech, Inc.INDUSTRY | 26 | Dec 13, 2019 | clinicaltrials |
| NCT02471846 | A Study of GDC-0919 and Atezolizumab Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 158 | Genentech, Inc.INDUSTRY | 4 | Oct 22, 2019 | clinicaltrials |
| NCT00833963 | A Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Trastuzumab, Pertuzumab in Combination With Trastuzumab, or Ado-Trastuzumab Emtansine(MotHER) | completed | — | 20 | Genentech, Inc.INDUSTRY | 1 | May 16, 2019 | clinicaltrials |
| NCT01846416 | A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR] | completed | Phase 2 | 138 | Genentech, Inc.INDUSTRY | 5 | Jan 8, 2019 | clinicaltrials |
| NCT02457793 | A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 24 | Genentech, Inc.INDUSTRY | 1 | Nov 20, 2018 | clinicaltrials |
| NCT02301988 | A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer | completed | Phase 2 | 151 | Genentech, Inc.INDUSTRY | 3 | Oct 17, 2018 | clinicaltrials |
| NCT01615068 | An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry) | completed | — | 1,007 | Genentech, Inc.INDUSTRY | 1 | Jul 16, 2018 | clinicaltrials |
| NCT02146313 | A Study Evaluating the Safety and Pharmacokinetics of DMUC4064A in Participants With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer | completed | Phase 1 | 35 | Genentech, Inc.INDUSTRY | 1 | Jun 21, 2018 | clinicaltrials |
| NCT02273973 | A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI) | completed | Phase 2 | 334 | Genentech, Inc.INDUSTRY | 22 | May 21, 2018 | clinicaltrials |
| NCT01207323 | A Study of the Safety and Pharmacokinetics (PK) of MEHD7945A in Participants With Locally Advanced or Metastatic Epithelial Tumors | completed | Phase 1 | 66 | Genentech, Inc.INDUSTRY | 2 | May 1, 2018 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials